Regeneron’s Casirivimab and Imdevimab Receive the US FDA’s EUA as the First Combination Therapy for COVID-19

November 23, 2020 Auto Bot Casirivimab, Clinical Trials, EUA, Imdevimab, patients, receives, Regeneron, US FDA’s 0

Shots:

  • The US FDA has issued a EUA for casirivimab (1,200mg) + imdevimab (1,200mg) administered together for mild to mod. COVID-19 in adults and pediatric patients aged ≥12yrs. weighing at least 40kg [~88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19
  • The EUA is based on a P-II study that showed a reduction in hospitalization or ER visits in patients at high risk for disease progression within 28days after treatment and a reduction in viral loads
  • Initial doses of Ab cocktail will be made available to ~300,000 patients, with no medication out-of-pocket costs, under the US government allocation program

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Fox Business

The post Regeneron’s Casirivimab and Imdevimab Receive the US FDA’s EUA as the First Combination Therapy for COVID-19 first appeared on PharmaShots.